Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded partnership with Eton Pharmaceuticals (“Eton”), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. As part of this expanded collaboration, Optime Care will serve as the specialty pharmacy provider of a third product for Eton, dispensing the newly acquired GALZIN® (zinc acetate), an FDA-approved product used in the treatment of the ultra-rare metabolic condition of Wilson Disease.
Health Technology Insights: Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey
“We are excited to expand our partnership with Eton and continue to support specialty patient populations through tailored programs, personalized communications and comprehensive treatment support,” says Julie Price, pharmacist in charge, Optime Care. “Our expert care teams understand the complexities of rare diseases, providing guidance at every stage to improve access to vital therapies, streamline care coordination and ensure financial assistance is available to those who need it most.”
Leveraging innovative, proprietary technology platforms and patient engagement tools, Optime Care’s expert teams, including specially trained patient care coordinators, deliver end-to-end solutions that enhance patient outcomes and improve medication adherence.
Health Technology Insights: Nona Biosciences Integrates AI to Enhance Antibody Discovery
“GALZIN® is an essential therapy for patients with Wilson Disease. We look forward to partnering with Optime Care to offer comprehensive patient support through our Eton Cares program which will greatly improve therapy access and affordability, including $0 co-pay for commercially eligible patients. Optime Care has been a trusted partner, ensuring timely medication delivery and specialized care for those with complex conditions, so we are pleased to expand our partnership,” says Sean Brynjelsen.
GALZIN® is FDA-approved for the maintenance treatment of patients with Wilson Disease who have been initially treated with a chelating agent. It is estimated that less than 5,000 patients in the United States are currently being treated for Wilson Disease.
Health Technology Insights: Factor 7 Medical Expands Leadership and Service Areas
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – GlobeNewswire
